SOUTH JORDAN, Utah, July 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023.
Merit will hold its investor conference call on the same day (Tuesday, July 25, 2023) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).
To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.
A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at merit.com.
ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is a leading global manufacturer and marketer of healthcare technology. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,100 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.
Contacts: | ||
PR/Media Inquiries: Teresa Johnson Merit Medical +1-801-208-4295 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-443-213-0509 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$90.89 |
Daily Change: | 0.32 0.35 |
Daily Volume: | 619,280 |
Market Cap: | US$5.300B |
April 09, 2025 March 27, 2025 March 25, 2025 March 10, 2025 February 25, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load